Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 37 of 43

Adverse Effects: SGAs Versus SGAs (2 of 2)

For other adverse events in direct comparisons, there is limited evidence of no statistically significant difference between second-generation antipsychotics (SGAs) for effects on insulin levels and glucose control, extrapyramidal symptoms, and sedative effects. The strength of evidence in support of these conclusions is low.

The risk of elevated prolactin is 2.6 times greater with risperidone than with olanzapine (from 1.7x to 5x). The strength of evidence for this conclusion is moderate.

The evidence from other head-to-head comparisons is insufficient to permit conclusions about differences in prolactin levels.

Study durations were typically too short to evaluate adverse effects on some important outcomes such as insulin and glycemic control.